-+ 0.00%
-+ 0.00%
-+ 0.00%

Verastem flags RAMP 201 biomarker data for late-breaking oral presentation at IGCS 2026

PUBT·09/24/2026 12:31:11
Listen to the news
Verastem flags RAMP 201 biomarker data for late-breaking oral presentation at IGCS 2026
  • Verastem flagged new molecular profiling and tumor biomarker analysis from Phase 2 RAMP 201 in recurrent low-grade serous ovarian cancer.
  • Findings will be presented Oct. 2, 2026 at the IGCS Annual Global Meeting as a late-breaking oral session.
  • Prior RAMP 201J Phase 2 results in Japanese patients were already reported; an oral presentation is scheduled at the same meeting.
  • The program supports the AVMAPKI FAKZYNJA CO-PACK franchise, which holds accelerated FDA clearance for KRAS-mutated recurrent disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260923864779) on September 24, 2026, and is solely responsible for the information contained therein.